AARTIPHARM

Current Performance - Highest ever standalone quarterly revenue of ₹613 Cr (up 47% YoY), EBITDA of ₹136 Cr (up 84% YoY) with 22.2% margin, and PAT at ₹66 Cr. - Segment revenue contribution: Xanthine derivatives & allied products 50%, API & intermediates 30%, CDMO/CMO 13%, and others 6%. Management Guidance & Outlook - Maintained CDMO segment growth target of 40% to 50% for FY27. - Targeting CDMO revenue milestone of ₹1,000 Cr ($100 Mn) over the next 2-3 years, driven primarily by 10-12 key commercial projects. - Expected annual revenue growth of 10% to 15% for the API & intermediate segment. Capex & Expansions - Total capex expected around ₹350–₹400 Cr in FY27, with ~₹300 Cr CWIP being capitalized by Q3/H2 FY27. - Xanthine capacity ramp-up on track to reach full expanded nameplate capacity of 9,600 MT, targeting ~8,800 MT operational volume over the next 2 years. - Atali Phase 2 dedicated block expected to commercialize in H2 FY28. Growth Drivers & Pipeline - CDMO project pipeline currently stands at 59 active projects (39 commercial, 20 under development). - Setting up peptide and oligonucleotide research facility, expected to be operational by the end of FY27 to capture high-value customer business in FY28. - Ongoing de-bottlenecking in oncology/anti-cancer APIs to support regulated market growth.

- Audio recording of the Earnings Conference Call for Q2 ended September 30, 2026 has been uploaded on the company's website. - Web link to access the recording has been provided.

- Aarti Pharmalabs Limited submitted its Investor Presentation for Q2 FY27. - The company highlights 220+ products, 7 manufacturing units, and 3 USFDA approved units. - Reported AA- credit rating with a low net debt-to-equity ratio of 0.37x. - International sales constitute 61% and domestic sales constitute 39% of total geographical sales for H1 FY27.

Q2 FY27 Consolidated Revenue ₹610.45Cr vs ₹418.33Cr (▲45.9% YoY) EBITDA ₹140.00Cr vs ₹63.71Cr (▲119.7% YoY) PAT ₹71.47Cr vs ₹20.49Cr (▲248.8% YoY) EBITDA Margin 22.9% vs 15.2% (▲770bps)

- Piyush Lakhani resigned as Chief Financial Officer (CFO) and Key Managerial Personnel effective October 30, 2026, to pursue outside opportunities. - Vibha Thakkar appointed as CFO and KMP effective October 31, 2026. - Board also approved unaudited standalone financial results for Q2 and H1 ended September 30, 2026.

- Shri Piyush Lakhani resigned as Chief Financial Officer (CFO) and KMP, effective October 30, 2026. - Smt. Vibha Thakkar appointed as new CFO and KMP w.e.f. October 31, 2026. - Board approved unaudited financial results for Q2 and H1 ended September 30, 2026.

- Aarti Pharmalabs Limited submitted financial results for the period ended September 30, 2026 to the Exchange.

- Aarti Pharmalabs Limited has revamped its official website to improve design, navigation, and accessibility. - The revamped website remains accessible at the existing URL: www.aartipharmalabs.com. - The intimation is made pursuant to Regulation 46 of the SEBI (LODR) Regulations, 2015.

- Aarti Pharmalabs Limited approved the grant of 850 stock options to eligible employees under the 'APL Performance Stock Option Plan- 2023' (PSOP 2023). - The grant was approved by the Nomination and Remuneration Committee on October 28, 2026. - The exercise price is set at ₹5 per option.

Concall Schedule Concall Date: October 29, 2026 Concall Time: 03:30 PM IST

- Aarti Pharmalabs Limited has filed a Writ Petition before the Hon'ble High Court of Gujarat at Ahmedabad. - The petition challenges the order dated August 29, 2026, passed by the Office of the Superintendent of Stamps, Gandhinagar, Gujarat. - The challenged order levied a stamp duty and penalties totaling ₹59.50 Crore regarding the Scheme of Arrangement (Demerger) sanctioned by the Hon'ble NCLT.

- Aarti Pharmalabs Limited announced the reconstitution of its Nomination and Remuneration Committee. - The reconstitution was approved by the Board of Directors on September 30, 2026, and is effective from October 01, 2026. - New committee includes Smt. Jeenal Savla as Chairperson, along with Dr. Vinay Nayak, Shri Pradeep Thakur, and Shri Rashesh Gogri as members.

- Trading window closed from October 01, 2026. - Closure remains until 48 hours after declaration of Q2 FY27 financial results. - Date of the Board Meeting will be announced in due course.

- Rajendra Gogri ceased as Non-Executive Non-Independent Director (effective Sep 22, 2026). - Hetal Gogri Gala re-designated from Managing Director to Whole-time Director (effective Oct 1, 2026). - Rashesh C. Gogri appointed as Managing Director (from Non-Executive Director) (effective Oct 1, 2026).

- Investor Presentation at 7th AGM on Sep 22, 2026. - Targets 15-18% Revenue & EBITDA CAGR over 3-4 years. - FY26 consolidated financials not comparable YoY due to JV accounting changes. - ~₹400 Cr capex for FY26; similar FY27 outlook, with Greenfield and Brownfield expansions.

- Aarti Pharmalabs received an order levying ₹59.50 Crores (stamp duty and penalty) related to its 2022 demerger. The company plans to challenge the order.

- Shri G.M. Naidu, Senior Management Personnel (Manufacturing/ Sr. General Manager / Chief of Operations), has resigned due to personal commitments and professional aspirations. His resignation was tendered on June 10, 2026, and he will be relieved from services on August 31, 2026.

- Submitted the Business Responsibility and Sustainability Report for the Financial Year 2025-26. - Filed as per Regulation 34(2)(f) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. - The report details the company's ESG performance, policies, and management processes, with the full report available on its website.

- Final Dividend for FY 2025-26 of ₹2.00/- per equity share (40%). - Record Date for final dividend payment is Tuesday, September 15, 2026. - The dividend will be paid on or before Tuesday, October 20, 2026, subject to approval at the AGM on September 22, 2026.

New Filing detected. See link for details.

- Aarti Pharmalabs Limited has uploaded the audio recording of its Investors/Analyst Earnings Conference Call. - The call was regarding the unaudited financial results for the first quarter ended June 30, 2026. - The recording is accessible via the link: https://www.aartipharmalabs.com/q1-fy-27.

- Aarti Pharmalabs Limited submitted an Investor Presentation related to its Q1 FY27 results. - The presentation provides a company overview, highlighting its manufacturing capabilities, R&D, and key milestones. - Geographical sales for Q1 FY27 were reported as 40% Domestic and 60% International. - The presentation includes historical standalone revenue and EBITDA margins up to Q1 FY26, but detailed comparative financial results for Q1 FY27 (Revenue, EBITDA, PAT) are not provided in this document.

New Filing detected. See link for details.

New Filing detected. See link for details.

New Filing detected. See link for details.

New Filing detected. See link for details.